Fairchem Organics Ltd

- There is no mention of any current or future fundraising through debt or equity in the transcript. - The company has completed its product development and investments for expansion, indicating no immediate capital requirement. - Management focuses on improving capacity utilization and product mix rather than seeking new external funding. - No explicit plans for raising funds via debt or equity were discussed during the call.

- The company has completed major investments related to new product development and plant trials primarily in Q1 and Q2 of FY24. - Currently, no significant ongoing capital expenditures or investments are indicated; process stabilization is in place. - Expansion or capacity enhancement is expected mainly through better utilization and scaling up of existing capacities rather than fresh capex. - Focus is on commercialization and scaling up of the newly developed high-value product, isosteric acid, rather than capital-intensive expansions. - Future growth is expected to come from improved capacity utilization, product mix, and market expansion, particularly with isosteric acid, rather than fresh large-scale capital investment.

- The company anticipates growth in volumes processed, with Q2 volume processed up 9% quarter-on-quarter. - Topline growth is linked to raw material prices (refined oil price fluctuating between ₹90-140), making revenue difficult to quantify precisely. - Capacity utilization is currently around 65%, expected to increase, supporting volume growth. - New product, isosteric acid, expected to commence commercial shipments in Q3/Q4 FY24, contributing to growth. - Paint industry seasonality affects quarterly sales; Q2 is traditionally lean. - Expansion and product development investments are complete; focus now on improving quantities sold and operational efficiency. - Expects gradual margin improvement to 15%-16% by FY25 due to product mix, capacity utilization, and raw material cost control. - Long-term revenue growth aligned with growth in the organized paint industry and other diverse applications, especially for dimer acid and isosteric acid products.

- Fairchem aims to achieve an EBITDA of around Rs.150 crores within the next couple of years, up from Rs.100 crores earlier, driven by margin recovery and volume growth. - EBITDA margins are expected to improve gradually, targeting 14%-16% range, potentially reaching 15% by FY25 with stable raw material costs, improved capacity utilization (~65% currently), and new product sales (isosteric acid). - Isosteric acid, a high-value export product (100% export, unique in India), is anticipated to start commercial shipments soon, contributing to margins and revenue growth. - Volumes processed increased by 9% quarter-on-quarter, and growth correlates with the paint industry, especially decorative segments. - China dumping impact is receding, supporting margin recovery. - The company sees margin improvement driven by a mix of product mix enhancement, raw material cost control, new products, and operating leverage, expecting more stable and standardized performance from Q3 FY24 onwards. - EPS growth will follow operational improvements and margin expansion.

- The company has substantial orders already for the new high-value product, isosteric acid. - Commercial shipments for isosteric acid are expected to commence once approvals and stability tests (90 to 120 days) are completed, likely starting in Q1 of the next year. - Approvals for isosteric acid from major paint players, including Grasim and JSW, have already been secured. - The company continues to retain all its existing customers and is optimistic about sales growth with new products. - Orders tied up with new paint plants indicate improved demand and order inflows in the coming days.